key: cord-1001699-igtwjiul
authors: Cohen, Barrie; Rubinstein, Rebecca; Gans, Melissa D.; Deng, Lily; Eisenberg, Rachel; Rubinstein, Arye
title: COVID-19 Infection in Ten Common Variable Immunodeficiency Patients in New York City
date: 2020-11-18
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2020.11.006
sha: 36c9b851b827754144e4881b0f8bc8dc801a7ad0
doc_id: 1001699
cord_uid: igtwjiul

nan

The authors have no conflicts of interest to disclose. 77 78 immunodeficiency, is characterized by hypogammaglobulinemia, impaired vaccine responses, 80 and recurrent sinopulmonary infections 1 . While known risk factors for more severe COVID-19 81 infection include older age, hypertension, obesity, and cardiovascular disease 2 , the association of 82 immunocompromised patients and severity of COVID-19 infection is not well established. 83

Studying specific immunocompromised cohorts may clarify risk of morbidity and mortality to 84 these patients from COVID-19 infection. A case series by Quinti et al. 3 

with CVID and two with agammaglobulinemia, all of whom recovered except one, suggesting 86 perhaps a similar mortality to the general population. Here, we assess the severity of infection, 87

need for hospitalization and mortality in a cohort of patients with CVID at our center. were deceased from non-COVID causes and 84 declined inclusion or were unable to be reached 103 and lacked chart data ( Figure E1 in the online repository). COVID-19 infection was confirmed in 104 ten patients ( Table 1 ). Seven of these ten patients were on immunoglobulin (IG) replacement 105 therapy (RT). One patient declined IGRT due to noncompliance and the others due to a relatively 106 low infection burden and instead opted for observation. The overall utilization rate of IGRT in 107 our cohort was 75% (102/135), similar to the COVID-19 positive patients (7/10). Three patients 108 had well identified co-morbidities for severe COVID-19 disease including hypertension (HTN), 109 diabetes mellitus (DM) and age. Eight of ten patients had baseline lymphopenia with total counts 110 less than 1,500 cells/mm 3 (Table 2) recovered. The patient requiring hospitalization had multiple known risk factors for severe 124 COVID-19, explaining the need for hospitalization. Consistent with prior case series in CVID 125 and agammaglobulinemia patients 3,4 , our cohort had high rates of recovery and did not appear to 126 have a higher mortality compared to the general population. This cohort likely had a milder 127 course than seen in Quinti et al 3 , as the majority of patients reviewed here were younger in age. 128

Despite lymphopenia, seen in eight of ten patients, all of the patients recovered and overall had 129 mild courses. This is in agreement with reports of HIV patients, in whom T-cell counts did not 130 predict disease severity 5 . A recent analysis of patients with immune mediated inflammatory 131 disease showed that known risk factors of age, HTN and DM were more likely to predict severe 132 disease, notably, the hospitalization rate was lower among those receiving biologics or JAK 133 inhibitors, suggesting that biologics are not associated with severe COVID-19 infection 6 . This is 134 in line with our cohort, in whom both patients on biologic therapy did not require hospitalization. 135

IGRT was utilized in 7/10 patients, similar to our general cohort. While the authors feel 136 that IGRT may have contributed to the patients' recoveries, three patients who were not on IGRT 137 also recovered, complicating this conclusion. Additionally, there was insufficient data to draw a 138 correlation between the ability to mount an antibody response and the patients' 139

Collectively, impaired B and T-cell function, lymphopenia and biologic therapy do not 141 appear to increase COVID-19 disease severity. Rather, the dysregulation of the myeloid 142 compartment, including resident lung macrophages, may in fact be the driver of inflammation, 143 and distinguish severe COVID-19 from mild cases 7 . Interestingly, ibrutinib, targeting BTK 144 6 (expressed on B-cell and myeloid derived cells) is theorized to protect against macrophage 145 induced lung injury in a small case series 8 . 146

Limitations of this study include the likely underreported incidence of COVID-19 147 infection due to incomplete medical records, the inability to reach patients, false negative NAAT, 148 lack of testing, or asymptomatic patients who were never tested. Additionally, several COVID-149 19 positive patients were no longer followed at our center and therefore recent laboratory data 150 and IGRT dosing were unavailable. Other limitations include small sample size, subjectivity to 151 recall bias by utilizing a survey, and its retrospective nature. 152

In conclusion, in our cohort of 135 patients with CVID, there was no mortality and low 153 morbidity of COVID-19 infection, suggesting the severity of infection in this cohort was 154 typically mild, and that these patients are at standard risk for severe disease. These results are 155 reassuring to providers caring for patients with CVID. Further research is needed to elucidate the 156 mechanism of severe COVID-19 disease and how it impacts patients with primary and secondary 157 immunodeficiency. Table 1 . Clinical characteristics of 10 CVID patients with COVID-19 infection. 188 189 Table 2 . Summary of phenotypic and immunologic data in 10 patients with CVID collected 190 before COVID-19 pandemic. 191 Figure E1 . Inclusion of patient cohort.

International Consensus Document (ICON): Common Variable 162

Therapy, and Mortality in Covid-19

for B cells in COVID-19? Lesson from patients with agammaglobulinemia

Two X-linked 169 agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover

Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. The 173

Immune-Mediated Inflammatory Diseases -Case Series from New York

A distinct 178 innate immune signature marks progression from mild to severe COVID-19